41,024 reports of this reaction
3.0% of all Enbrel reports
#6 most reported adverse reaction
INJECTION SITE ERYTHEMA is the #6 most commonly reported adverse reaction for Enbrel, manufactured by Immunex Corporation. There are 41,024 FDA adverse event reports linking Enbrel to INJECTION SITE ERYTHEMA. This represents approximately 3.0% of all 1,364,746 adverse event reports for this drug.
Patients taking Enbrel who experience injection site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE ERYTHEMA is a less commonly reported adverse event for Enbrel, but still significant enough to appear in the safety profile.
In addition to injection site erythema, the following adverse reactions have been reported for Enbrel:
The following drugs have also been linked to injection site erythema in FDA adverse event reports:
INJECTION SITE ERYTHEMA has been reported as an adverse event in 41,024 FDA reports for Enbrel. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE ERYTHEMA accounts for approximately 3.0% of all adverse event reports for Enbrel, making it a notable side effect.
If you experience injection site erythema while taking Enbrel, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.